SynthesisMuscle & nerve2025
Serum Biomarkers for Traumatic Peripheral Nerve Injury: A Systematic Review.
Synthesis in Muscle & nerve, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diagnosing the severity of a peripheral nerve injury or compression, and assessing its potential for recovery, remain clinical challenges. An objective and easily quantifiable serum-based biomarker that reflects axonal health would be a valuable diagnostic adjunct in the treatment of patients with peripheral nerve pathology. We therefore performed a review of the published literature using search strategies created for serum biomarkers and traumatic peripheral nerve injuries with both standardized index terms (i.e., MeSH, Emtree) and relevant key words. This yielded a total of 4626 combined results. Data was extracted from 12 studies (6 animal studies, 6 human studies). The biomarkers identified in this review ranged from axonal specific markers like neurofilament light chain (NfL) to more generalized markers such as lipid profiles and cytokines. The biomarker in this review deemed most promising for future use in the diagnosis and prognostication of peripheral nerve injury is serum NfL given its specificity for the nervous system and its dynamic behavior after nerve injury in animal models. Further work assessing its sensitivity and specificity to traumatic and compressive peripheral nerve injury may lay the foundation for widespread clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.